Sarcopenia (muscle loss with age)
The default decline of muscle and strength across decades: why it matters more than it sounds, and the two levers with real support behind them.
Definition
Sarcopenia is the progressive loss of muscle mass, strength and function that accompanies aging by default. It begins earlier than most people assume — the slide is generally underway from mid-adulthood — and accelerates in later decades. Clinically it’s diagnosed with formal criteria (grip strength, walking speed, measured muscle mass); as a lay concept, it’s the answer to why jars, stairs and getting off the floor become the events they become.
Why it matters more than it sounds
Muscle in later life is not cosmetic. Strength is the infrastructure of independence — standing from a chair, catching a stumble before it becomes a fall, carrying shopping, recovering from illness or surgery. Sarcopenia sits upstream of falls, frailty and loss of independence, which is why geriatric medicine treats declining strength as a warning light rather than a fact of life. Notably, strength tends to decline faster than muscle size, and predicts outcomes at least as well — which is convenient, because strength is the part that responds fastest to training.
Lever one: resistance training
The best-supported intervention, and not by a small margin. Muscle retains the ability to adapt at every age studied — trials in people in their eighties and nineties show meaningful gains in strength and function. The training that works in later life looks unheroic: progressive resistance work a couple of times a week, at honest effort, continued indefinitely. The exercise entry covers the broader picture; sarcopenia is the specific reason strength work stops being optional as decades pass.
Lever two: adequate protein
Muscle is built from what’s eaten, and appetite often declines exactly when needs stop declining. Geriatric nutrition guidance commonly emphasises making sure protein doesn’t quietly fall away in later life — older adults are a group frequently advised toward the higher end of intake discussions, alongside their resistance training rather than instead of it. Specific targets are individual territory; the direction of the advice is consistent.
What’s contested
Pharmaceutical approaches to sarcopenia remain an active research field with, to date, no approved silver bullet; supplement marketing runs far ahead of its evidence, as usual. The two boring levers above are where the support actually lives.